RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 501–600 of 764
Fleming, I. R., Hannan, J. P., Swisher, G. H., Tesdahl, C. D., Martyr, J. G., Cordaro, N. J., Erbse, A. H., & Falke, J. J. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2022.115019 · Cited by 9
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
Stauffer, S., Roth, J. S., Hernandez, E. R., Kowalczyk, J. T., Sealover, N. E., Hebron, K. E., James, A. E., Isanogle, K. A., Riffle, L. A., Ileva, L. V., et al. (2024) · Cancers · doi:10.3390/cancers16132320 · Cited by 8
“…to inhibit RAS activation downstream of RTKs, such as with an SHP2 inhibitor, as has been previously reported [19], would not completely prevent the activation of compensatory signaling pathways such as the PI3K/AKT [73] or JAK/STAT [74] pathways, which can be activated in a RAS-independent manner.”
BackgroundKim, E., Samanta, A., Cheng, H. S., Ding, Z., Han, W., Toschi, L., & Chang, Y. (2015) · Molecular BioSystems · doi:10.1039/c5mb00525f · Cited by 6
Bialkowska, A. B., & Yang, V. W. (2012) · Future Oncology · doi:10.2217/fon.12.19 · Cited by 7
HER2 Activation Factors in Arsenite-Exposed Bladder Epithelial Cells
Jin, P., Liu, J., Wang, X., Yang, L., Zhou, Q., Lin, X., & Xi, S. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy202 · Cited by 7
Metabolic Response of Pancreatic Carcinoma Cells under Treatment with Dichloroacetate
Feuerecker, B., Biechl, P., Veltkamp, C., Saur, D., & Eisenreich, W. (2021) · Metabolites · doi:10.3390/metabo11060350 · Cited by 8
“downstream effectors are affected, such as Raf/Mek/Erk, phosphatidylinositol 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase-1 (Pdk1)/Akt, RalGDS/p38MAPK, Rho and Rac, p120GAP [2,9,10].”
BackgroundAnalysis of context-specific KRAS–effector (sub)complexes in Caco-2 cells
Ternet, C., Junk, P., Sevrin, T., Catozzi, S., Wåhlén, E., Heldin, J., Oliviero, G., Wynne, K. J., & Kiel, C. (2023) · Life Science Alliance · doi:10.26508/lsa.202201670 · Cited by 9
“PLA was performed to evaluate the recruitment of p110 ɑ -PI3K to Ras, using NaveniFlex MR (Navinci Diagnostics).”
InfluentialWang, J., Al-Majid, D., Brenner, J. C., & Smith, J. D. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00993-3 · Cited by 6
“PIP 3 then phosphorylates and activates protein kinase B ( AKT ) to promote cell survival and proliferation by inter-acting with further targets downstream, such as mammalian target of rapamycin (mTOR) [51, 52].”
BackgroundAl-Qattan, M. M., Balwi, M. A. A., Al-Zayed, E. M., Al-Sohaibani, M. O., Gelidan, A. G., & Alsheiban, S. (2020) · Journal of Hand Surgery (European Volume) · doi:10.1177/1753193420922459 · Cited by 6
“It is noteworthy that both pathways interact with each other, since RAS is a direct stimulator of P13K activity (Castellano and Downward, 2011).”
BackgroundWhy isn’t an oncogenic mutation in KRAS enough to induce and sustain transformation?
Iovanna, J., & Dusetti, N. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105110 · Cited by 7
Παπαδάκος, Κ. Σ., Ekström, A., Slipek, P., SKOURTI, E. K., Reid, S., Pietras, K., & Blom, A. M. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02565-1 · Cited by 5
“The three breast cancer cell lines analyzed gave inconsistent results in terms of phospho-activated Akt and mTOR levels.”
BackgroundInfluentialKRas plays a negative role in regulating IDO1 expression
Peng, X., Lee, E., liang, J., Colon, T. M., Tran, F., Choi, B. H., & Dai, W. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102167 · Cited by 5
Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis
Zheng, K., Hao, F., Medrano-Garcia, S., Chen, C., Guo, F., Morán-Blanco, L., Rodríguez, S., Torres-Ruiz, R., Peligros, M. I., Vaquero, J., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06029-y · Cited by 6
Wang, Z. (2012) · InTech eBooks · doi:10.5772/48623 · Cited by 5
“Endosome fusion is regulated by specific cytosolic and membrane-associated protein factors, including a group of Ras-like small guanosine triphosphatases (GTPases) called Rabs [90-92].”
InfluentialDeconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies
Yamaguchi, R., & Perkins, G. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061258 · Cited by 5
Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors
Smith, A. J. H., Pawar, M. D., Dort, M. E. V., Galbán, S., Welton, A. R., Thurber, G. M., Ross, B. D., & Besirli, C. G. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0126 · Cited by 5
Gadea, A., Hernández‐Muñoz, I., Vicente, A., Andrades, E., García-Calvente, M., Camacho, L., Fernández‐Rodríguez, C., Bellosillo, B., Pujol, R. M., & Toll, A. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106296 · Cited by 5
Ali, Z., & Hermawan, A. (2022) · INDONESIAN JOURNAL OF PHARMACY · doi:10.22146/ijp.2346 · Cited by 6
“Intracellular signaling then produces PI3K transcriptional activator, which, in turn, produces RAS, RAF, p38MAPK, and p53 in the RTKRAS signaling pathway (Castellano & Downward, 2011).”
BackgroundMydin, R. B. S. M. N., Mahboob, A., Sreekantan, S., Saharudin, K. A., Qazem, E. Q., Hazan, R., & Wajidi, M. F. F. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2421 · Cited by 5
Yokoyama, N., Nakayama, H., & Iwabuchi, K. (2023) · Cells · doi:10.3390/cells12020322 · Cited by 6
“These findings indicate that PI3K/AKT is a downstream effector of Kras signaling and that AKT phosphorylates GSK3β [38,157,158].”
BackgroundABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
Golovine, K. V., Abalakov, G., Lian, Z., Chatla, S., Karami, A. L., Chitrala, K. N., Madžo, J., Nieborowska-Skorska, M., Huang, J. Y., & Skórski, T. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00810-0 · Cited by 5
Boente, M. D. C. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6654-3_27 · Cited by 5
Júnior, R. A. A., Souza, C. M., de Azevedo, M. L. V., Netto, M. R. M., Baldin, R. K. S., Sebastião, A. P. M., Soares, L. F. D. P., Tullio, L. F., & de Noronha, L. (2017) · Journal of Coloproctology · doi:10.1016/j.jcol.2017.08.005 · Cited by 4
Bagian Patologi Anatomi Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, B., Erida, Y., Usman, H. A., Bagian Patologi Anatomi Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, B., Yulianti, H., Bagian Patologi Anatomi Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, B., Hernowo, B. S., & Bagian Patologi Anatomi Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, B. (2015) · Indonesian Journal of Clinical Pharmacy · doi:10.15416/ijcp.2015.4.4.264 · Cited by 5
Telechea‐Fernández, M., Rodríguez‐Fernández, L., García, C., Zaragozá, R., Vinã, J. R., Cervantes, A. M. R., & García–Trevijano, E. R. (2018) · Oncotarget · doi:10.18632/oncotarget.23888 · Cited by 8
“Different lines of evidence support that tumors with both KRAS and PI3K mutations are unresponsive to the inhibition of MEK alone or the PI3K alone [30–33].”
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells
Poli, A., Fiume, R., Mongiorgi, S., Zaurito, A. E., Sheth, B., Vidalle, M. C., Abdul-Hamid, S., Kimber, S. T., Campagnoli, F., Ratti, S., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100722 · Cited by 5
Tummala, H. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.9.3 · Cited by 5
Equalizing the information amounts of protein and mRNA by information theory
Adıgüzel, Y. (2017) · Biosystems · doi:10.1016/j.biosystems.2017.05.003 · Cited by 5
“…of proteins at transient conformational 394 states (Gray et al., 2012) under certain circumstances is another relevant aspect, if the proteins 395 are not mutants that are frozen in a transient state like that in a constitutively active state 396 (Kwon et al., 2010; Castellano and Downward, 2011).”
BackgroundHigh-Throughput Multiomics Profiling of Model Systems Using the AVITI24 PlatformPreprint
Lopez, T., Honigfort, D. J., Mah, A., Thompson, C., Dien, V. T., Dawood, M., Frankel, E., Fuller, D., Jamison, C., Kelley, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.03.651997 · Cited by 7
“For instance, phosphorylation of heat shock protein 27 (HSP27) enhances cell survival by stabilizing the cytoskeleton and inhibiting caspase activation, cooperating with anti-apoptotic BCL-2 family proteins to block apoptosis [23,24,25,26].”
The Potential of Phytochemicals to Overcome Multidrug Resistance in Metastatic Melanoma
Maphutha, J., Twilley, D., Dawood, M., Efferth, T., & Lall, N. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202502536 · Cited by 4
Isoform‐specific functions of Ras in T‐cell development and differentiation
Bodhale, N. P., Nair, A., & Saha, B. (2023) · European Journal of Immunology · doi:10.1002/eji.202350430 · Cited by 4
Han, D., Zhou, Y., Zhang, K., Gai, C., Zhang, P., Chai, X., Zhuo, X., Zhao, Q., Zou, Y., & Zhu, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117568 · Cited by 5
Sun, R., Hu, Y., Liu, X., Lin, Y., Lv, D., Li, W., Fu, L., & Jiang, F. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107460 · Cited by 4
Bjorklund, G. R., Rees, K. P., Balasubramanian, K., Hewitt, L. T., Nishimura, K. J., & Newbern, J. M. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050570 · Cited by 4
“Upstream RASopathy variants in the NF1, SHP2 (encoded by Ptpn11 ) and RAS proteins have been shown to modulate PI3K/Akt, PKC and/or Rho/ROCK activity, in addition to the ERK1/2 pathway (Anastasaki and Gutmann, 2014; Brown et al., 2012; Castellano and Downward, 2011; Kaul et al., 2015).”
Hálková, T., Bunganič, B., Traboulsi, E., Minárik, M., Zavoral, M., & Benešová, L. (2024) · Genes · doi:10.3390/genes15101302 · Cited by 5
“Under physiological conditions, Ras is again inactivated in a short time by the hydrolysis of GTP [5–8].”
BackgroundThe RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Optimization of oncogene expression through intra‐population competition
Ferreira, J. P., & Wang, C. L. (2013) · Biotechnology Journal · doi:10.1002/biot.201300037 · Cited by 4
“[7] Castellano, E.”
BackgroundMise au point sur l’inhibition de la voie Ras-MAPK : les inhibiteurs de Mek
Baldini, C., Duchemann, B., Hollebecque, A., Routier, É., Varga, A., Gazzah, A., Bahleda, R., Besse, B., Soria, J., & Massard, C. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1632 · Cited by 4
Exploring the molecular role of endostatin in diabetic neuropathy
Mukherjee, T., Behl, T., Sehgal, A., Bhatia, S., Singh, H., & BUNGAU, S. G. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06205-3 · Cited by 5
Hamid, M., Serafin, A. M., & Akudugu, J. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174612 · Cited by 6
Multifocal intradural extramedullary ependymoma, MYCN amplified: illustrative case
Shields, L. B. E., Sun, D. A., Highfield, H. A., LaRocca, R. V., Spalding, A. C., Sinicrope, K. D., Zhang, Y. P., & Shields, C. B. (2022) · Journal of Neurosurgery Case Lessons · doi:10.3171/case22141 · Cited by 6
“The p110 subunit is responsible for the enzyme’s phosphorylation activity and is involved in the PI3K-AKT-mTOR and the Ras-Raf-MEK-ERK pathways that mediate cellular growth and survival.(16,17) Activating mutations, copy number gains, and overexpression of PIK3CA are associated with cancer progression.”
BackgroundAlpelisib decreases nevocytes of congenital melanocytic nevi
Tomás‐Velázquez, A., López‐Gutiérrez, J. C., de Andrea, C., Reyes‐Múgica, M., Salgado, C. M., & Redondo, P. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19736 · Cited by 4
“16 In fact, it has been shown that PI3K signalling is indispensable to maintain transformed growth in RAS mutant cell lines both in vitro and in xenografts in mice.”
BackgroundSosa, Y. J., Sosa, H. M., Epiter‐Smith, V., Topaz, G. R., & Stieglitz, K. A. (2020) · Engineering materials · doi:10.1007/978-3-030-31403-3_9 · Cited by 5
Insulin at 100 years – is rebalancing its action key to fighting obesity-related disease?
Brierley, G. V., & Semple, R. K. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049340 · Cited by 4
Dong, Y., Saglietti, C., Bayard, Q., Espín-Pérez, A., Carpentier, S., Buszta, D., Tissot-Renaud, S., Dubois, R., Kamburov, A., Kang, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.01.621259 · Cited by 4
“…the areas showed a mixture of signaling pathways, such as 13 IL-6/JAK/STAT3 signaling 14 , mTORC1 signaling 15 , and p53 pathways that show signs of tumor proliferation, and pathways such as KRAS signaling down 13 and TGF-beta signaling 16 suggesting tumor suppression 16 and immune infiltration.”
BackgroundMechanisms and current advances in treating KRAS-mutated lung cancer
Chao, C. H.-Y., & Di, Y. P. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.08.001 · Cited by 10
“114 Once RAF proteins are activated, they phosphorylate MEK, which, in turn, activates extra-cellular signal-regulated kinases 1 and 2 (ERK1/2).”
Subcellular Cartography of the Phosphoinositide Multiverse
Ricci, M. M. C., Weckerly, C. C., & Hammond, G. R. V. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2025.159706 · Cited by 5
Nieto-Coronel, M. T., Ortega-Gómez, A., Yacab, R. A., Fernández-Figueroa, E. A., López‐Camarillo, C., Marchat, L. A., la Vega, H. A.-D., & Ruíz‐García, E. (2024) · International Journal of Breast Cancer · doi:10.1155/2024/9058033 · Cited by 3
Earnhardt-San, A. L., Baker, E. C., Cilkiz, K. Z., Cardoso, R. C., Ghaffari, N., Long, C. R., Riggs, P. K., Randel, R. D., Riley, D. G., & Welsh, T. H. (2025) · Genes · doi:10.3390/genes16020191 · Cited by 3
“One of these effects is the regulation of apoptosis, either through pro-or anti-apoptotic signaling, in which the DMGs from our data set play a particular role [109,110].”
Pan-Cancer Analysis Identifies a Ras-Related GTPase as a Potential Modulator of Cancer
Hsueh, H., Gumpper, K., Poelstra, J. W., Pitter, K. L., & Cruz‐Monserrate, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094419 · Cited by 3
“These activated pathways promote tumorigenesis, cancer initiation, and resistance to apoptosis and chemotherapy [2].”
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 7
Hallway gossip between Ras and PI3K pathways
Emanuel, P. D. (2014) · Blood · doi:10.1182/blood-2014-03-559039 · Cited by 3
PI3King the right partner: unique interactions and signaling by p110ß
Dbouk, H. A. (2015) · Postdoc Journal · doi:10.14304/surya.jpr.v3n6.8 · Cited by 4
“Akt has multiple downstream substrates with a common consensus motif for phosphorylation [17], and can lead to regulation of various pathways, most prominently activation of mTORC1 via phosphorylation and inhibition of Tuberous Sclerosis Complex 2 (TSC2) which, together with TSC1, form a GTPaseactivating protein (GAP)…”
BackgroundInfluentialModulation of CD44, EGFR and RAC Pathway Genes (WAVE Complex) in Epithelial Cancers
Tata, P., Gondaliya, P., Sunkaria, A., Srivastava, A., & Kalia, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190222143044 · Cited by 3
Lee, K.-T. D., Chen, L., Li, W.-S., & Lee, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1039376 · Cited by 3
“The Ras/Raf/ERK signaling and PI3K/Akt signaling pathway are highly interconnected (Castellano and Downward, 2011).”
BackgroundHsu, C.-H., Weng, P., Chen, M., Yeh, C., Setiawan, S. A., Yadav, V. K., Wu, A. T. H., Tzeng, D. T. W., Gong, J., Yang, Z., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110329 · Cited by 3
Cellular signals integrate cell cycle and metabolic control in cancer
Akekawatchai, C., & Jitrapakdee, S. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.01.002 · Cited by 4
Exploring pathway interactions to detect molecular mechanisms of disease: 22q11.2 deletion syndrome
Shin, W., Kutmon, M., Mina, E., van Amelsvoort, T., Evelo, C. T., & Ehrhart, F. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02953-6 · Cited by 4
“Since GRB2 plays an important role in PI3K activation pathways [54, 55], GRAP2 (GRB2 related adaptor protein 2) can be considered to take part in the same pathway.”
BackgroundCase Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
Максимовна, П. Е., Lebedeva, A., Kuznetsova, O. A., Belova, E., Kavun, A., Ivanov, M. V., Fedyanin, M., Tryakin, A. A., Mileyko, V., & Nosov, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1245547 · Cited by 3
“Despite the fact that the PIK3CA variant was indeed oncogenic, the MTB concluded that targeting this alteration with a PI3K inhibitor Alpelisib would have unlikely resulted in response to therapy due to the constitutively activated KRAS and the interplay between RAS and PI3K (4).”
BackgroundChallenging diagnosis of Kaposiform lymphangiomatosis: Unveiling a rare primary lymphatic disorder
Ospino, R., & Brookmeyer, C. (2023) · Radiology Case Reports · doi:10.1016/j.radcr.2023.10.078 · Cited by 3
Signaling Molecules: Importance in Health and Disease Conditions
Banerjee, J., Limaye, D., Pathan, A., Banerjee, S., & Tiwari, A. K. (2025) · The Receptors · doi:10.1007/978-3-031-81991-9_2 · Cited by 5
Autophagy Flux Correlates with Upregulation of AKT-1 in RAS Mutated Colon Cancer Cells
Behrouj, H., Mahmoudzadeh, A. P., Ghavami, S., & Mokarram, P. (2021) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.30476/mejc.2021.85836.1307 · Cited by 3
Nakagawa, K., Nagano, T., Katasho, R., Iwasaki, T., & Kamada, S. (2022) · FEBS Letters · doi:10.1002/1873-3468.14477 · Cited by 3
Wang, J., Wang, H., Shen, Y. H., Dong, L., Wang, H., Zhang, S., Cao, Y.-X., & Cao, L. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000788 · Cited by 5
The Endeavours in RAS Inhibition - the Past, Present, and Future
Hussain, J., Kirubakaran, S., & Ravi, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163044 · Cited by 4
Basu, B., Ghosh, S., Das, S., & Das, A. K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_28 · Cited by 3
MiR-708-5p as a Predictive Marker of Colorectal Cancer Prognosis
Fedatto, P. F., de Carvalho, T. I., de Oliveir, J. C., Antônio, D. S. M., Pezuk, J. A., Tirapell, D. P. D. C., Féres, O., da Rocha, O. J. R., Scrideli, C. A., Tone, L. G., et al. (2016) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2016.05.01.2 · Cited by 3
“Mutations of the RAS family members are hallmarks of CRC [34-35], and their oncogenic activation stimulates a wide range of downstream signaling pathways, including PI3K/AKT [35-36].”
BackgroundKinase and Phosphatase Effector Pathways in T Cells
Myers, D. R., & Roose, J. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.11006-9 · Cited by 3
Geoffroy, A., Habbas, K., Zámbó, B., Schramm, L., Duchon, A., Flatter, E., Fouillen, L., Zumsteg, J., Heintz, D., Mandel, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.22.301762 · Cited by 4
“The excess of DAG originating from the loss of DGKk activity could play a prominent role in FXS pathomechanism because DAG, through activation of its main effector protein kinase C (PKC) (32), could be responsible of mitogen activated protein kinase (MAPK/ERK) (46) or Ras/phosphatidylinositol-3-kinase (PI3K)/AKT pathw…”
BackgroundPartan, E. S., Blei, F., Chamlin, S. L., Davies, O. M. T., Drolet, B. A., Frieden, I. J., Karakikes, I., Lin, C., Mancini, A. J., Metry, D. W., et al. (2021) · medRxiv · doi:10.1101/2021.08.05.21261553 · Cited by 3
Liu, H., Yu, L., Majerčiak, V., Meyer, T. J., Yi, M., Johnson, P. F., Cam, M., Lowy, D. R., & Zheng, Z. (2024) · eLife · doi:10.7554/elife.102681.3 · Cited by 5
Rho GTPase and Rho Kinase Signaling in Tissue Contractility and Intraocular Pressure Regulation
Raghavan, S., & Pattabiraman, P. P. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl44589 · Cited by 2
Qu, Z., & Wang, X. (2026) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203251409639 · Cited by 2
Poloni, J. D. F., & Bonatto, D. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25156 · Cited by 2
“Additionally, the PI3k/Akt pathway, which may be regulated by Cer and S1PR1, is required for the expression of cardiac transcription factors in mesodermal cells and has been associated with cardiac commitment, lamellipodia formation, and cytoskeletal reorganization via Rac1 activation [Faustino et al., 2008; Putnam et…”
BackgroundPlatinum-resistance and AKT Over-expression in Ovarian Cancer
Hahne, J. C. (2015) · International Journal of Gynecology & Clinical Practices · doi:10.15344/2394-4986/2015/110 · Cited by 2
“Furthermore it was demonstrated that also the PI3K/AKT-pathway controls the Ras/Raf/MEK/ERK-signal transduction cascade; phosphorylated AKT decreased the Raf activity [43-45].”
BackgroundKoo, J., Wang, S., Kang, N., Hur, S. J., & Bahk, Y. Y. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.7.256 · Cited by 2
“ple downstream effector molecules that modulate diverse cellular signaling activities, and there are strong indications of feedback and crosstalk with huge signaling networks (5, 6).”
BackgroundThe Tyrosine Phosphatase SHP2: A Key Molecule Linked both Type 2 Diabetes and Cancers?
Xiangdong, Z. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000175 · Cited by 4
“So far, several different mechanisms have been explored to account for the abnormal activation of Ras signaling pathways in tumorigenesis, including mutations in Ras, loss of GAP proteins, overexpression of RTKs (such as EGFR), and also abnormal phosphorylation of tyrosine phosphatase upstream of Ras/Erk [48].”
BackgroundAl-Qattan, M. M. (2021) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000003391 · Cited by 5
T cells: a dedicated effector kinase pathways for every trait?
Bahl, K., & Roose, J. P. (2021) · Biochemical Journal · doi:10.1042/bcj20210006 · Cited by 2
The landscape of genetic alterations of UVB ‐induced skin tumors in DNA repair‐deficient mice
Yoshioka, A., Nakaoka, H., Fukumoto, T., Inoue, I., Nishigori, C., & Kunisada, M. (2022) · Experimental Dermatology · doi:10.1111/exd.14634 · Cited by 2
Aljuhani, T. A., Shaik, N. A., Alqawas, R. T., Bokhary, R., Almutadares, M., Mahdi, H. B. A., Alrayes, N. M., El-Harouni, A. A., Elango, R., Banaganapalli, B., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1498295 · Cited by 3
Altered PI3K/AKT/mTOR Signaling Pathway and Cancer Stem Cells
Ertay, A. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_5 · Cited by 3
Jani, V., Sonavane, U., & Sawant, S. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11138-1 · Cited by 3
“The earlier studies suggest that the binding of RAS is essential to increase the proximity of the kinase domain to the membrane, where the PIP2 resides and undergoes phosphorylation [98, 99].”
Exploring Multi-Target Therapeutic Strategies for Glioblastoma via Endogenous Network Modeling
Yao, M., Zhu, X., Chen, Y.-C., Yang, G.-H., & Ao, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073283 · Cited by 2
RASopathies. Part I: Genetics and therapeutic considerations
Jaeger, Z. J., Ramirez, N. M., Osborne, A. D., Staser, K. W., King, K. A., Bayliss, S. J., & Mann, C. M. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.05.1455 · Cited by 2
Gruet, M., Xu, Y., An, L., Ma, Y., Balcells, C., Tyson, K., Evangelista, L. C., Spear, S., Xu, Y., McKinney, F., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09223-0 · Cited by 4
“RAS proteins exert their functions through several effector pathways, particularly PI3K signalling 15 .”
Serum from morbidly obese patients affects melanoma cell behavior in vitro
Mocellin, D., Bratti, L. D. O. S., Silva, A. H., Assunção, L. S., Kretzer, I. F., & Filippin-Monteiro, F. B. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-979020201000x42e19375 · Cited by 2
Proliferation and Differentiation Programs of Developing B Cells
Werner, M., & Jumaa, H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397933-9.00006-0 · Cited by 6
Targeting Metabolic Vulnerabilities in RAS-Mutant Cells
Rao, A. D., & McArthur, G. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00011-4 · Cited by 3
MacNeil, I. A., Khan, S. A., Sen, A., Soltani, S. M., Burns, D. J., Sullivan, B. F., & Laing, L. G. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00798-9 · Cited by 3
Takamoto, Y., Arima, Y., & Saya, H. (2016) · Genes to Cells · doi:10.1111/gtc.12435 · Cited by 2
Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal AdenocarcinomaPreprint
Ciecielski, K. J., Mulero‐Sánchez, A., Berninger, A., Cañas, L. R., Bosma, A. R., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472574 · Cited by 2
“For those most common mutations, targeted inhibitors have not yet been developed; therefore, most translational studies have been aimed at blocking downstream RAS effectors mainly in the MAPK or PI3K-AKT pathways (18-21).”
BackgroundLiu, H., Yu, L., Majerčiak, V., Meyer, T., Yi, M., Johnson, P. F., Cam, M., Lowy, D. R., & Zheng, Z. (2024) · eLife · doi:10.7554/elife.102681.1 · Cited by 2
Wang, X., Ding, L., Sun, S., Loo, S. K., Chen, L., Li, T., Wang, M.-T., Pennathur, A., Huang, Y., & Gao, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.23.650349 · Cited by 2
Li, T., Li, T., Zhang, H., Liu, C., Li, M., Wang, C., Zheng, Y., Zhang, L., Long, X., Shi, S., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812325 · Cited by 1
“We speculated that this might be due to KRAS promoting tumor growth through activation of the PI3K/Akt pathway [30], while LA inhibited the PI3K/Akt pathway [13,31,32].”
BackgroundAdaptor protein Abelson interactor 1 in homeostasis and disease
Petersen, M., & Dubielecka, P. M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01738-z · Cited by 1
“KRAS activation is upstream of signaling processes directly affected by ABI1 including PI3K/AKT and Rac/ CDC42 [185, 186], and also affects MAPK cascade and NF-κB activation [187, 188].”
BackgroundThe multifaceted significance of phosphoinositides in endocytic trafficking
Xie, C., & Shi, A. (2026) · FEBS Letters · doi:10.1002/1873-3468.70268 · Cited by 3
Gul, A., Zhong, Y., Aili, M., Xie, C. H., Talifu, A., Huo, S., Kuerban, Y., Yalkun, M., Li, Z. J., & Dong, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-45457-6 · Cited by 1
“Castellano and Downward et al. have reported that membrane recruitment involves direct binding to GEFs and GAPs, leading to their activation and translocation, which is a critical step in Kras mutation and pathogenicity 75–77 .”
Angiogenesis-related microRNAs and signalling pathways in canine mammary tumours
Abbate, J. M., Giosa, D., Anjomanibenisi, M., Arfuso, F., Giannetto, A., Capra, A. P., Riolo, K., Lanteri, G., & Brunetti, B. (2026) · The Veterinary Journal · doi:10.1016/j.tvjl.2026.106767 · Cited by 1
SNAILs promote G1 phase in selected cancer cells
Wu, Y., Xue, J., Zhou, L., Deng, L., Shang, Y., Liu, F., Mo, X., & Lü, Y. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3148 · Cited by 1
“However, KRAS can interact with the PI3K/Akt pathway (8), and then affect GSK3β.”
Background
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.